Regeneron Pharmaceuticals said it will acquire 23andMe's business. What happened to 23andMe? Should you delete your data?

Biotechnology company Regeneron will acquire 23andMe out of bankruptcy for $256 million, with a plan to keep the DNA-testing ...

Regeneron, a biotech company, will acquire 23andMe for $256 million and vowed to comply with the genetic testing company's ...

Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...

The sale was for $256 million and is expected to be complete by the third quarter of this year, according to a Regeneron news ...

How exactly 23andMe will shake out after the Regeneron purchase is to be seen. The company has taken a dramatic fall in ...

Regeneron Pharmaceuticals announced Monday it plans to purchase human genetics and biotechnology firm 23andMe from bankruptcy ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...

Regeneron is acquiring “substantially all” of 23andMe’s assets for $256 million following a bankruptcy auction.

Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.

Regeneron Pharmaceuticals has promised to comply with 23andMe's existing privacy polices while also using data to fuel drug discovery.